Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational study

Annals of the Rheumatic Diseases

Volumn 62, Issue 10, 2003, Pages 944-951

  Aletaha, D ^a   Stamm, T ^a   Kapral, T ^a   Eberl, G ^b   Grisar, J ^a   Machold, K P ^a   Smolen, J S ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SURVIVAL RATE;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; SULFASALAZINE; TIME FACTORS; TREATMENT FAILURE;

EID: 0141427819     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.10.944     Document Type: Article

References (38)

1. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
2. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983;287:1102-4.
3. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
4. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:495-505.
5. Jeurissen ME, Boerbooms AM, van De Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991;114:999-1004.
6. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
7. Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:30-5.
8. Furst DE. Aggressive strategies for treating rheumatoid arthritis: has the case been proven? Lancet 2000;356:183-4.
9. Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995;34:87-90.
10. Wilske KR, Healey LA. The need for aggressive therapy of rheumatoid arthritis. Rheum Dis Clin North Am 1993;19:153-61.
11. Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van De Putte LB, van Riel PL. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8.
12. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002;29:1639-45.
13. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
14. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
15. Grisar J, Eselboeck D, Koeller M, Aringer M, Stummvoll G, Pietschmann P, et al. Leflunomide reduces transendothelial migration [abstract]. Arthritis Rheum 2001;44(suppl):S297.
16. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
17. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
18. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
19. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15(suppl 17):S27-38.
20. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991;18:1008-14.
21. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-18.
22. Aletaha D, Smolen JS. Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. Arthritis Rheum 2002;47:181-8.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl 1996;44:102-6.
25. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
26. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
27. van der Heijde DM, van't HM, van Riel PL, van de Putte LB. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993;20:538-41.
28. Atkinson JP. C-reactive protein: a rheumatologist's friend revisited. Arthritis Rheum 2001;44:995-6.
29. Breslow NE, Edler L, Berger J. A two-sample censored-data rank test for acceleration. Biometrics 1984;40:1049-62.
30. Conover RJ. Practical nonparametric statistics. 3rd ed New York: Wiley, 1999.
31. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
32. Aletaha D, Smolen J. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD therapies. Rheumatology (Oxford) 2002;41:1367-74.
33. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686-9.
34. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
35. Ellis SJ, Adams RF. The cult of the double-blind placebo-controlled trial. Br J Clin Pract 1997;51:36-9.
36. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
37. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
38. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75:69-73.